Relmada Therapeutics

$RLMD, currently undergoing their Phase 3 program of REL-1017, which aims to offer a revolutionary treatment for major depressive disorder, is down today after releasing Q4 earnings this morning. CEO Sergio Traversa in regards to REL-107 said the program is “steadily proceeding, and we expect top line data in the second half of 2024.”

Share This Article

 

About the Author

Relmada Therapeutics

Joey Ramson